ATR vs. IQV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ATR and IQV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
IQV’s market capitalization of 28.41 billion USD is significantly greater than ATR’s 10.64 billion USD, highlighting its more substantial market valuation.
IQV carries a higher beta at 1.29, indicating it’s more sensitive to market moves, while ATR (beta: 0.59) exhibits greater stability.
| Symbol | ATR | IQV |
|---|---|---|
| Company Name | AptarGroup, Inc. | IQVIA Holdings Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| CEO | Stephan B. Tanda | Ari Bousbib |
| Price | 161.04 USD | 164.24 USD |
| Market Cap | 10.64 billion USD | 28.41 billion USD |
| Beta | 0.59 | 1.29 |
| Exchange | NYSE | NYSE |
| IPO Date | April 23, 1993 | May 9, 2013 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ATR and IQV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ATR
14.87%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Equity of 14.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
IQV
20.74%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, IQV’s Return on Equity of 20.74% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ATR
11.90%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Invested Capital of 11.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
IQV
8.14%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
IQV’s Return on Invested Capital of 8.14% is in line with the norm for the Medical - Diagnostics & Research industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ATR
10.42%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
ATR’s Net Profit Margin of 10.42% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
IQV
8.61%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
IQV’s Net Profit Margin of 8.61% is aligned with the median group of its peers in the Medical - Diagnostics & Research industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ATR
14.17%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
ATR’s Operating Profit Margin of 14.17% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
IQV
13.85%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
IQV’s Operating Profit Margin of 13.85% is around the midpoint for the Medical - Diagnostics & Research industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ATR | IQV |
|---|---|---|
| Return on Equity (TTM) | 14.87% | 20.74% |
| Return on Assets (TTM) | 8.18% | 4.88% |
| Return on Invested Capital (TTM) | 11.90% | 8.14% |
| Net Profit Margin (TTM) | 10.42% | 8.61% |
| Operating Profit Margin (TTM) | 14.17% | 13.85% |
| Gross Profit Margin (TTM) | 36.41% | 34.72% |
Financial Strength
Current Ratio
ATR
1.25
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ATR’s Current Ratio of 1.25 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
IQV
0.82
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
IQV’s Current Ratio of 0.82 falls into the lower quartile for the Medical - Diagnostics & Research industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ATR
0.41
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
ATR’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Instruments & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
IQV
2.43
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
With a Debt-to-Equity Ratio of 2.43, IQV operates with exceptionally high leverage compared to the Medical - Diagnostics & Research industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio
ATR
11.17
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
ATR’s Interest Coverage Ratio of 11.17 is in the upper quartile for the Medical - Instruments & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
IQV
3.21
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
IQV’s Interest Coverage Ratio of 3.21 is positioned comfortably within the norm for the Medical - Diagnostics & Research industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ATR | IQV |
|---|---|---|
| Current Ratio (TTM) | 1.25 | 0.82 |
| Quick Ratio (TTM) | 0.85 | 0.82 |
| Debt-to-Equity Ratio (TTM) | 0.41 | 2.43 |
| Debt-to-Asset Ratio (TTM) | 0.23 | 0.53 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.19 | 3.76 |
| Interest Coverage Ratio (TTM) | 11.17 | 3.21 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ATR and IQV. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ATR
1.12%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.12%, ATR offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
IQV
0.00%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
IQV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ATR
31.58%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ATR’s Dividend Payout Ratio of 31.58% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
IQV
0.00%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
IQV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ATR | IQV |
|---|---|---|
| Dividend Yield (TTM) | 1.12% | 0.00% |
| Dividend Payout Ratio (TTM) | 31.58% | 0.00% |
Valuation
Price-to-Earnings Ratio
ATR
28.83
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
In the lower quartile for the Medical - Instruments & Supplies industry, ATR’s P/E Ratio of 28.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
IQV
21.63
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
In the lower quartile for the Medical - Diagnostics & Research industry, IQV’s P/E Ratio of 21.63 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
ATR
2.54
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
ATR’s Forward PEG Ratio of 2.54 is within the middle range of its peers in the Medical - Instruments & Supplies industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
IQV
2.04
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
IQV’s Forward PEG Ratio of 2.04 is within the middle range of its peers in the Medical - Diagnostics & Research industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ATR
2.99
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
ATR’s P/S Ratio of 2.99 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
IQV
1.83
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
In the lower quartile for the Medical - Diagnostics & Research industry, IQV’s P/S Ratio of 1.83 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ATR
4.18
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
ATR’s P/B Ratio of 4.18 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
IQV
4.83
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ATR | IQV |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.83 | 21.63 |
| Forward PEG Ratio (TTM) | 2.54 | 2.04 |
| Price-to-Sales Ratio (P/S, TTM) | 2.99 | 1.83 |
| Price-to-Book Ratio (P/B, TTM) | 4.18 | 4.83 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 29.67 | 13.14 |
| EV-to-EBITDA (TTM) | 14.80 | 12.13 |
| EV-to-Sales (TTM) | 3.25 | 2.66 |